MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Home・Aandelen Lijst・Vivani Medical

Vivani Medical

Gesloten

1.5 11.94

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.3599999999999999

Max

1.54

Belangrijke statistieken
By Trading Economics
Werknemers	37

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+194.12% upside

Dividenden
By Dow Jones
Volgende Winsten	30 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-21M 83M
Vorige openingsprijs	-10.44
Vorige sluitingsprijs	1.5

Vivani Medical Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 jan 2026, 23:49 UTC

Belangrijke Marktbewegers

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 jan 2026, 21:12 UTC

Belangrijke Marktbewegers

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 jan 2026, 21:00 UTC

Acquisities, Fusies, Overnames

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 jan 2026, 20:29 UTC

Belangrijke Marktbewegers

Chip Makers Gain After Trump Calls Off European Tariffs

21 jan 2026, 20:04 UTC

Belangrijke Marktbewegers

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 jan 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 jan 2026, 23:34 UTC

Marktinformatie

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 jan 2026, 22:39 UTC

Winsten

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 jan 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

21 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

21 jan 2026, 21:35 UTC

Acquisities, Fusies, Overnames

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 jan 2026, 21:19 UTC

Winsten

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 jan 2026, 20:45 UTC

Acquisities, Fusies, Overnames

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 jan 2026, 20:36 UTC

Marktinformatie

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 jan 2026, 20:31 UTC

Marktinformatie

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 jan 2026, 20:27 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 jan 2026, 20:27 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

21 jan 2026, 20:27 UTC

Marktinformatie

Was It a 'TACO' Event? -- Market Talk

21 jan 2026, 20:26 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 jan 2026, 20:23 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 jan 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 jan 2026, 20:19 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse Group Agrees to Buy Allfunds

21 jan 2026, 20:08 UTC

Winsten

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 jan 2026, 20:03 UTC

Marktinformatie

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 jan 2026, 19:51 UTC

Marktinformatie

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 jan 2026, 19:43 UTC

Marktinformatie

U.S. Ethanol Production Expected to Slip -- Market Talk

21 jan 2026, 19:31 UTC

Marktinformatie

Gold Settles at Fresh All-Time High -- Market Talk

21 jan 2026, 19:24 UTC

Winsten

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 jan 2026, 19:10 UTC

Marktinformatie

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 jan 2026, 18:57 UTC

Marktinformatie

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Peer Vergelijking

Prijswijziging

Vivani Medical Prognose

Koersdoel

By TipRanks

194.12% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD 194.12%

Hoogste 4 USD

Laagste 4 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vivani Medical - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Vivani Medical - Dist in de afgelopen 3 maanden.

Financieel

Over Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.